Kelly Lawrence W & Associates Inc Alkermes Plc. Transaction History

Kelly Lawrence W & Associates Inc

  • $413 Million
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018
SELL
$40.56 - $51.36 $48,672 - $61,632
-1,200 Closed
0 $0
Q4 2017

Feb 14, 2018
SELL
$47.69 - $55.39 $6.04 Million - $7.01 Million
-126,600 Reduced 99.06%
1,200 $66,000
Q3 2017

Nov 15, 2017
BUY
$49.16 - $54.45 $6.28 Million - $6.96 Million
127,800
127,800 $6.5 Million

Others Institutions Holding ALKS

# of Institutions
376
Shares Held
173M
Call Options Held
231K
Put Options Held
158K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.63B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Kelly Lawrence W & Associates Inc Portfolio

Follow Kelly Lawrence W & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kelly Lawrence W & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Kelly Lawrence W & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email